Posted by Michael Wonder on 17 Jan 2018
NICE approves CDF funding for Janssen’s Darzalex
17 January 2018 - NICE is backing NHS use of Janssen’s Darzalex via the Cancer Drugs Fund for some adults with previously treated multiple myeloma.
Darzalex (daratumumab) is a humanised monoclonal antibody that works by binding to a signalling molecule found on the surface of multiple myeloma cells called CD38, to trigger the patient's own immune system to attack and kill the cancer cells.
NICE’s appraisal committee has ruled that the drug can not be recommended for routine use within its marketing authorisation for treating relapsed and refractory multiple myeloma in adults, because uncertainties in the clinical data available mean that cost effectiveness estimates are unreliable.
